C

Caidya

Global CRO delivering end-to-end clinical development

Senior Clinical SAS Programmer

Full-TimePosted on 10/22/2026
No salary listed
Senior
Bachelor's
Remote in India
RemoteRemote work from India.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A bachelor's degree in Mathematics, Biostatistics, Statistics, or Computer Science, or equivalent work experience demonstrating the required knowledge and skills.
  • At least 5 years of experience providing advanced statistical programming services.
  • Advanced knowledge of SAS DATA step, PROC IMPORT, PROC SQL, and ODS programming.
  • Experience identifying common data-entry errors and creating reports that help data managers query data points efficiently.
  • Knowledge of clinical trial databases and clinical-trial data reports is preferred.
  • Knowledge of data merging, transposition, sorting, and other data-manipulation concepts.
  • Proficiency in SAS data programming and reporting using PROC REPORT and ODS.
  • Ability to create programs that anticipate and identify potential problems.
  • Ability to review requests and determine the best approach to maximize the usefulness of reports or listings.
  • Ability to solve problems using available resources with little oversight.
  • Computer skills, including a clear understanding of Microsoft Excel functions and formatting.
  • Effective time-management and organizational skills.
  • Ability to handle multiple projects at once.
  • Ability to work remotely as needed.
Responsibilities
  • Program complex data checks and data-reconciliation reports.
  • Create special reports using SAS and other tools as requested by the Data Management department.
  • Merge external data with EDC data and check for consistency.
  • Transform SAS datasets, delimited data files, and other file types into Excel for data review.
  • Automate reports as needed to improve efficiency for team members.
  • Collaborate and communicate with team members locally and around the world across different functional areas.
  • Advise on efficiencies for presenting data during clinical-trial cleaning processes to help identify potential data issues.
  • Mentor and assist junior programmers.
  • Perform other duties as assigned.
Desired Qualifications
  • Ability to create visualizations using SAS graphics language.
  • Understanding of UNIX, Windows, and PowerShell commands.

About the company

Caidya is a global contract research organization that provides outsourced clinical development services for biopharmaceutical and medical device companies. It covers the full lifecycle from pre-IND strategy and early-phase development through late-stage trials, regulatory submissions, and post-marketing surveillance, delivered via flexible models like standalone projects, full-service partnerships, and functional service provider arrangements, supported by its Clarity data platform that offers near real-time trial visibility and compatibility with Medidata Rave and Veeva. Its competitive edge comes from the merged legacy of Clinipace and dMed Global, strong leadership under Dr. Lingshi Tan, a broad global footprint including North America and China, and an emphasis on data-driven, transparent trial delivery. The goal is to help clients bring therapies to market efficiently and compliantly through high-quality, scalable trial execution across global programs.

Company Size

201-500

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$322.2M

Headquarters

Morrisville, North Carolina

Founded

2003

Get referred to Caidya

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 NMPA accepted partner MediLink's Tam-Peli NDA, validating China execution.
  • Caidya’s APAC-heavy model fits sponsors needing China speed and regulatory navigation.
  • Rubicon’s $165 million 2025 growth capital still funds expansion and integration.

What critics are saying

  • Combining Caidya and Simbec-Orion creates integration failure risk through 2026-2027.
  • CRO rivals Fortrea, ICON, and Medpace outspend Caidya on scale and technology.
  • Failed integration traps Caidya as a subscale CRO and forces retrenchment.

What makes Caidya unique

  • June 30, 2026 deal with Simbec-Orion adds Phase I clinical pharmacology to Caidya.
  • Barbara Lopez Kunz now runs a CRO spanning Europe, Americas, APAC, and China.
  • Michael Clay’s February 2026 COO hire deepens global delivery across 60 countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

-1%

2 year growth

-1%
Business Wire
Jul 1st, 2026
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution....

Associated Press
Feb 17th, 2026
Caidya appoints Michael Clay as COO to strengthen global clinical trial operations across Asia-Pacific

Caidya, a global clinical research organisation, has appointed Michael Clay as chief operating officer. Clay will oversee global operational delivery, client engagement and execution strategy across the US, Europe and Asia-Pacific. Clay brings extensive experience leading global clinical programmes across more than 60 countries, with particular expertise in Asia-Pacific operations. Most recently, he served as senior vice president of Global Project Delivery at Fortrea, where he managed over 500 global clinical trials. The appointment strengthens Caidya's operational capabilities, particularly in China and the broader APAC region. Caidya operates in more than 20 countries and conducts studies across over 50 countries, focusing on complex therapeutic areas including oncology, haematology and rare diseases.

Business Wire
Jan 16th, 2025
Caidya Announces $165 Million Strategic Growth Investment From Rubicon Founders

Caidya today announced the closing of a strategic growth investment of $165 million from funds managed by Rubicon Founders.

Business Wire
Jan 13th, 2025
Caidya Announces $165 Million Strategic Growth Investment From Rubicon Founders

Caidya announces $165 million strategic growth investment from Rubicon Founders.

FinSMEs
Jul 10th, 2021
dMed-Clinipace Closes US$50M Series C+ Financing

dMed-Clinipace, a Shangai, China- and Morrisville, NC-based global full-service Clinical Contract Research Organization (CRO), closed a US$50m Series C+ financing. The round was led by Springhill Fund, with participation from funds managed by Rock Springs Capital and Superstring Capital. They joined Series C lead investor Fidelity Management and Research Company LLC as well as other new […]